Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$2.8b

Amicus Therapeutics Future Growth

Future criteria checks 5/6

Amicus Therapeutics is forecast to grow earnings and revenue by 53.4% and 18.7% per annum respectively. EPS is expected to grow by 53.1% per annum. Return on equity is forecast to be 32.4% in 3 years.

Key information

53.4%

Earnings growth rate

53.1%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate18.7%
Future return on equity32.4%
Analyst coverage

Good

Last updated20 Jan 2025

Recent future growth updates

Recent updates

Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Dec 30
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Amicus Therapeutics: Cheap Heading Into 2025

Dec 27

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Nov 10
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18

'Boring' Amicus Therapeutics Is Making Progress

Sep 29

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

Earnings and Revenue Growth Forecasts

NasdaqGM:FOLD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20279592854213504
12/31/20267821492402649
12/31/20256373917624012
12/31/2024531-61-18-305
9/30/2024494-105-32-27N/A
6/30/2024456-120-48-42N/A
3/31/2024423-147-88-81N/A
12/31/2023399-152-77-69N/A
9/30/2023372-174-162-153N/A
6/30/2023351-185-133-127N/A
3/31/2023337-204-131-126N/A
12/31/2022329-237-170-167N/A
9/30/2022323-264-159-156N/A
6/30/2022321-281-172-168N/A
3/31/2022318-270-192-188N/A
12/31/2021306-250-206-202N/A
9/30/2021294-239-185-182N/A
6/30/2021282-252-203-200N/A
3/31/2021267-254-201-198N/A
12/31/2020261-277-237-233N/A
9/30/2020246-295-254-241N/A
6/30/2020227-293-272-255N/A
3/31/2020209-325-298-280N/A
12/31/2019182-356-270-250N/A
9/30/2019160-345-264-253N/A
6/30/2019131-442-340-330N/A
3/31/2019109-419-337-329N/A
12/31/201891-349-306-300N/A
9/30/201873-340-318-312N/A
6/30/201864-293N/A-228N/A
3/31/201849-279N/A-213N/A
12/31/201737-284N/A-214N/A
9/30/201725-273N/A-173N/A
6/30/201716-208N/A-165N/A
3/31/20179-211N/A-155N/A
12/31/20165-200N/A-150N/A
9/30/20162-184N/A-154N/A
6/30/2016N/A-175N/A-134N/A
3/31/2016N/A-152N/A-124N/A
12/31/2015N/A-132N/A-100N/A
9/30/2015N/A-110N/A-79N/A
6/30/20150-90N/A-73N/A
3/31/20151-77N/A-62N/A
12/31/20141-69N/A-52N/A
9/30/20142-60N/A-45N/A
6/30/20141-57N/A-44N/A
3/31/20141-58N/A-42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FOLD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: FOLD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FOLD is expected to become profitable in the next 3 years.

Revenue vs Market: FOLD's revenue (18.7% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: FOLD's revenue (18.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FOLD's Return on Equity is forecast to be high in 3 years time (32.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 01:05
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg